Kidney function on semaglutide — eGFR and UACR improvements

Dr.AddMedPHL said:

For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and…

The FLOW trial results on renal function and renal outcomes: semaglutide 1.0mg reduced the composite kidney outcome by 24% (HR 0.76, p=0.0003) in CKD patients with T2DM[1].

The trial was stopped early for efficacy — always a strong signal. GFR decline was 1.16 mL/min/1.73m²/year slower with semaglutide. This positions GLP-1 agonists alongside SGLT2 inhibitors as pillars of cardiorenal protection in T2DM.

Dr.AddMedPHL said:

For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and…

Agreed, and the size of the effect matters as much as its existence. Something real and small gets treated here as though it were real and decisive.

Ask again with the specifics and you will get a better answer than this one.

Dr.AddMedPHL said:

For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and…

Saving this. It is the first explanation that did not require me to already understand it.

From the other side of the consultation, briefly. It helps to say which part of this you are uncertain about. A precise question gets a precise answer; a general one gets everybody’s favourite anecdote.

Worth separating that from semaglutide, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

TrialNerd_Beth said:

It helps to say which part of this you are uncertain about.

Same experience, arrived at from the opposite direction. Nothing to add that would improve it.